This testosterone/estrone ratio will exert a powerful and considerable reactions to the emotional well being, as well as in sexual functions, libido, muscle mass and strength, energy, cardiovascular health, bone integrity and memory behavior.

It is advantageous that testosterone/estrogen ratio is directly influenced by the aromitazation and bioavailable levels of several other hormones, including DHEA projesterone, androstenedione, estrone aldosterone, cortisol, estradiol and dihydrotestoasterone. These hormones which directly effect testosterone and estrogen ratios, also directly effect emotional well being, as well as sexual function, libido, muscle mass, fat to lean muscle ratios, strength, energy, cardiovascular health, osteoporosis, memory and cognitive function, as well as risk for breast cancer and benign prostate hypertrophy.

It is well established, that as a human being ages, these testosterone/estrone ratios adjust and change with age, with increasing formation levels of estrone and a proportional decrease in the formation of testosterone.

It is known from the specification of U. S. Patent No. 4,598, 072 to Schweibert et. al dated July 1,1986 to provide for an aromatase inhibitor and an antiandrogen which generally is applicable for the treatment of prostatic hyperglania, incorporated herein by reference only.

Furthermore, it is known from the specification of U. S. Patent No. 5,972, 921 to Santti et. al dated October 26,1999 in the use of an aromatase inhibitor administered for the specific treatment for men for detrusor wrethral dyssynergia. This is incorporated herein for reference only.

It is also known from the specification of U. S. Patent No. 5,861, 389 to Radlmaier et. al dated January 19,1999 for specific treatment of only androgen deficiency in men using selective aromatase inhibitors. This is incorporated herein for reference only.

The present invention includes an anti-aromatase pharmaceutical or more specifically a nutraceutical composition in dose compound form comprising a formula in which each capsule or dose consists of: a. Nettle root extract (Uritica dioica) 16: 1 in the range of about 275 mg. to about 350 mg;

a. Nettle root extract (Uritica dioica) 16 : 1 in the range of about 275 mg. to about 350 mg; b. Pumpkin seed oil (cucubita pepo) in the range of about 150 mg. to about 205 mg. ; c. Pygeum Africanum tprunus africana) bark extract standardized to contain about 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg; and d. Chrysin in the range of about 475 mg. to about 550 mg.

However, the present invention also relates to a totally new use of a male hormone panel aromatasition structure with an androgen pathway as depicted at Table I and TI, also for breast cancer and other related treatments.

TABLE I £gbeHvtoosePwnd aIRF i-. CQX*Cll -i,. ofone t ,.. . at l.. t {Eslrne TABL1i Nermal w rsOA61 tablez F. 8p 61 TABLEZ IMBMiBngeofBhmmmmehMS Z-w. < 0 60-110 35 Wbw 72 k} Sl i . Top" ist-350 -S9 60w 26 l 35I_ SO 26- ffiãllS ~}

Both Tables I and II depict Aromatisation structure that are beneficial to the method of treatment of various ailments, for example, benign prostate hyperthrophy, some forms of breast cancer, and in the treatment of osteoporsis, etc.

Specifically, the present invention relates to a totally new application of several naturally occurring aromatase inhibitors which interupt several stages in the presented hormone panel (Table I), which illustrates the currently accepted normal aromatization sequence. This invention also incorporates for the first time, an inhibitor of sex hormone binding globulin which allows bioavailable hormone to remain active at target tissue sites for a longer period of time.

Suitably, the present invention includes an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Nettle root extract (Uritica dioica) 16: 1 of about 300 mg; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain about 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.

Conveniently, this invention is an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Pumpkin seed oil (Cucubita pepo) of about 175 mg; b. Nettle root extract (Uritica dioica) 16: 1 of about 300 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg; and d. Chrysin in the range of about 475 mg. to about 550 mg.

Advantageously, this invention resides in an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Phgeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.; b. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; c. Nettle root extract (Urtica dioica) 16: 1 of about 300 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.

Moreover, the present invention is an anti-aromatase capsule or dose in compound form comprising a formula in the pharmaceutical or nutraceutical composition of which each capsule or dose consists of: a. Chyrsin of about 500 mg.; b. Nettle root extract (Urtica dioica) of about 300 mg.; c. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; and d. Pygeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.

In addition, the invention resides in a method of treatment utilizing a pharmaceutical composition consisting of a dosage or capsule constituted by an anti-aromatase pharmaceutical or nutraceutical composition in dose compound form comprising a formula in which each capsule or dose consists of: a. Nettle root extract (Urtica dioica) 16: 1 in the range of about 275 mg. to above 350 mg.; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.

Also, the invention provides a method of treatment utilizing a pharmaceutical or nutraceutical composition consisting of a dosage or capsule constituted an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Nettle root extract (Uritica dioica) 16: 1 of about 300 mg.; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain about 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.

Furthermore, the invention assists a method of treatment utilizing a pharmaceutical or nutraceutical composition consisting of a dosage or capsule constituting an anti- aromatase capsule or dose compound form in which the composition for the maintenance of

testosterone/estrone ratios with the anti-aromatase composition being characterized by: a. Nettle root extract (Uritical dioica) 16: 1 of 275 mg. to above 350 mg.; b. Pumpkin seed oil (Cucubita pepo) of 150 mg. to about 205 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain about 12 to 14% of total sterols of 20 mg. to about 40 mg.; and d. Chrysin of 475 mg. to 550 mg.

Advantageously, a method of treatment utilizing a specific nutraceutical or pharmaceutical anti-aromatase composition so as to maintain the testerone/estrone ratios, said composition is characterized by: a. Chrysin of 500 mg.; b. Nettle root extract (Uritica dioica) of 300 mg.; c. Pumpkin seed oil (Cucubita pepo) of 175 mg.; and d. Pygeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and 25 mg.

The invention also includes a method of treatment utilizing a pharmaceutical or nutraceutical composition cosisting of a dosage or capsule constituting an anti-aromatase capsule or dose in compound form in which the composition consists of: a. Pygeum Africanum (Prunus africana) bark extract standardized to contain 13A total sterols and about 25 mg.; b. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; c. Nettle root extract (Urtica dioica) 16: 1 of about 300 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.

The invention furthermore includes a method of treatment utilizing a nutraceutical or a pharmaceutical composition consisting of a dosage or capsule constituted by an anti- aromatase capsule or dose in compound form comprising a formula in the composition of which each capsule or dose consists of: a. Chyrsin of about 500 mg.; b. Nettle root extract (Urtica dioica) of about 300 mg.; c. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; and d. Pygeum Africanum (Prunus africana) bark extract stadardized to contain 13% total sterols and about 25 mg.

An anti-aromatase nutraceutical or pharmaceutical composition, consisting of inc apsule or dose to contain: Nettle root extract (Urtica dioica) 16: 1 in the range of about 275 to 350 mg.

Pumpkin seed oil (Cucubita pepo) in the range of about 150 to 205 mg.

Pygeum Afiicanum (Prunus africana) bark extract standardized to contain at least 12 to 14% of total sterols in the range of about 20 to 40 mg. and Chrysin in the range of 475 to 550 mg.

This composition assists in the treatment of benign prostate hyperthropy and breast cancer etc.